Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Srdan Verstovsek, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Blueprint Medicines, Bristol‐Myers Squibb, Celgene, CTI BioPharma, Galena BioPharma, Genentech, Geron, Gilead Sciences, Incyte, Lilly Oncology, NS Pharma, Pfizer, Promedior, Roche, and Seattle Genetics.
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
John Mascarenhas, MD, has disclosed that he has received consulting fees from Incyte and Novartis and funds for research support from CTI Biopharma, Incyte, Janssen, Merck, Novartis, Promedior, and Roche.
Assistant Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
Associate Managing Editor
Senior Clinical Editor
Editorial Director, Hematology/Oncology
This program is intended for physicians and other healthcare providers who care for patients with polycythemia vera and myelofibrosis.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2018, through January 30, 2019:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
In this archived Webcast, Raajit K. Rampal, MD, PhD, provides expert perspectives on the diagnosis and optimal management of patients with polycythemia vera or myelofibrosis.
Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?
Shaji Kumar, MD, provides an overview of the latest research on smoldering multiple myeloma, with treatment strategies to consider for your patients.
In this CME-certified activity, Farhad Ravandi, MD, explores optimal current treatment of this rare leukemia, including standard systemic therapies and targeted approaches, as well as emerging therapies.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.